Bar Harbor Biotech Developing qPCR-Based Colorectal Cancer Risk Test
April 28, 2011
Bar Harbor Biotech Developing qPCR-Based Colorectal Cancer Risk Test
BRB, which is also developing similar tests for other cancers and autoimmune diseases, has partnered with lab testing services firm Clinical Reference Laboratory for clinical validation of its tests.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Qiagen Expands Companion Dx Portfolio with Three Licensing Deals; Exceeds 2012 QiaSymphony Placement Target
January 7, 2013 / GenomeWeb Daily News - SQI Streamlines Dx Development Pipeline, Ramps up Sales Effort for Tools and Services Business
August 28, 2012 / BioArray News - Ohio State Joins Coriell's Personalized Rx Project to Study Utility of Genomic Data in Patient Care
September 30, 2009 / Pharmacogenomics Reporter - Royalties Drive up GeneNews Q1 Revenues Sharply
May 16, 2013 / GenomeWeb Daily News - GenomeWeb Feature: The Unsteady March of Cancer Protein Biomarkers into the Clinic
May 10, 2013 / ProteoMonitor